** Drug developer Monopar Therapeutics' shares up 13% at $5.25 premarket
** Company signs agreement with AstraZeneca unit Alexion for the license to AZN's experimental drug being tested for Wilson disease, a rare genetic condition that causes the buildup of toxic copper levels
** Monopar will be responsible for future global development and drug commercialization activities
** Under deal terms, Monopar will pay Alexion an upfront in cash and equity in Monopar
** As of last close, Monopar stock has more than tripled YTD
(Reporting by Sruthi Narasimha Chari in Bengaluru)
((Sruthinarasimha.chari@thosmonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments